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OBJECTIVE—T cells and level of the cytokine interferon-g
(IFN-g) are increased in adipose tissue in obesity. Hedgehog
(Hh) signaling has been shown to potently inhibit white adipocyte
differentiation. In light of recent ﬁndings in neurons that IFN-g
and Hh signaling cross-talk, we examined their potential interac-
tion in the context of adipogenesis.
RESEARCH DESIGN AND METHODS—We used Hh reporter
cells, cell lines, and primary adipocyte differentiation models to
explore costimulation of IFN-g and Hh signaling. Genetic dissec-
tion using Ifngr1
2/2 and Stat1
2/2 mouse embryonic ﬁbroblasts,
and ultimately, anti–IFN-g neutralization and expression proﬁling
in obese mice and humans, respectively, were used to place the
ﬁndings into the in vivo context.
RESULTS—T-cell supernatants directly inhibited hedgehog
signaling in reporter and 3T3-L1 cells. Intriguingly, using blocking
antibodies, Ifngr1
2/2 and Stat1
2/2 cells, and simultaneous acti-
vation of Hh and IFN-g signaling, we showed that IFN-g directly
suppresses Hh stimulation, thus rescuing adipogenesis. We con-
ﬁrmed our ﬁndings using primary mouse and primary human
(pre)adipocytes. Importantly, robust opposing signals for Hh
and T-cell pathways in obese human adipose expression proﬁles
and IFN-g depletion in mice identify the system as intact in adi-
pose tissue in vivo.
CONCLUSIONS—These results identify a novel antagonistic
cross-talk between IFN-g and Hh signaling in white adipose tissue
and demonstrate IFN-g as a potent inhibitor of Hh signaling.
Diabetes 60:1668–1676, 2011
T
he World Health Organization (WHO) currently
estimates that more than 1 billion individuals
worldwide are overweight. Almost one-third of
these individuals are clinically obese, markedly
raising their chances of cardiovascular disease, type 2 di-
abetes, cancer, and stroke (1).
Interestingly, not all obesity results in metabolic disease,
and thus, it is not adiposity alone that contributes to adi-
pose tissue abnormalities (2–9). For instance, large, lipid-
loaded fat cells appear to be particularly important for
the development of obesity-related cardiovascular and
metabolic disorders. Increases in adipocyte size correlate
with higher production of inﬂammatory adipokines, and
increased circulating inﬂammatory markers are clinically
observed in patients with hypertrophic adipocytes com-
pared with fat mass–matched control subjects with smaller
fat cells. Exactly why this is the case remains to be proven;
one suggestion has been that the impaired function of large
adipocytes results from the relative hypoxia of the micro-
environment (2,3).
Poor expandability of the adipocyte pool, combined
with chronic low-grade inﬂammation, is thought to initiate
a vicious cycle that ultimately culminates in obesity with
full metabolic dysfunction, including insulin resistance
(10–13). Several studies have shown that in addition to
macrophages, the number of CD3
+ T cells is increased in
adipose tissue in obesity (14,15). Furthermore, genetic or
diet-induced obese (DIO) mouse models exhibit a prom-
inent and early inﬂux of cytotoxic CD8
+ T cells (16–19).
Local mRNA levels of the activated T-cell cytokine in-
terferon-g (IFN-g) are increased in adipose tissue of DIO
mice compared with lean controls, and IFN-g–deﬁcient
animals show signiﬁcantly decreased proinﬂammatory
gene expression and macrophage accumulation in adipose
tissue in obesity (20). In addition, IFN-g decreases insulin
sensitivity and suppresses differentiation in human adi-
pocytes (21,22). However, whether T-cell activation and
associated increases in IFN-g per se cause insulin resistance
in adipose tissue has been questioned (23). Indeed, mac-
rophage inﬁltration is the most robust discriminant between
insulin-sensitive (IS) and insulin-resistant (IR) individuals
with morbid obesity (24).
Hedgehog (Hh) signaling is an ancestral developmental
process directing embryonic differentiation and adult tissue
homeostasis through stem cell regulation and orchestration
of complex differentiation programs (25–28). Activation of
the Hh pathway is initiated by the Hh ligands, which release
inhibition of the Smoothened (Smo)-Patched (Ptch) dual-
receptor system at the cell surface, ultimately culminating
in translocation of the Gli transcription factors to the nu-
cleus and modulation of their target genes. Activation rein-
forces the signaling system as promoters of a number of
the signaling constituents themselves represent Gli-targets,
including Gli1 and Ptch1. We and others have demonstrated
that Hh signaling is important in adipose tissue differenti-
ation in vivo (29,30), speciﬁcally blocking white but not
brown adipocyte differentiation at an early stage (30). Of
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ORIGINAL ARTICLEnote, expression of Hh target genes is signiﬁcantly de-
creased in adipose tissue of genetic and DIO mouse models,
suggesting persistent inhibition of the pathway in obesity
(29).
Cross-talk between Hh and IFN-g signaling has been
described in some cells of the central nervous system (31–
33). Canonical Hh signaling has been shown to mediate
neuronal and oligodendroglial differentiation (34–37). In-
terestingly, IFN-g induces sonic Hh (Shh) mRNA expres-
sion in astroglia and neuronal stem cells (32) and has been
shown to contribute to medulloblastoma development by
reactivating Hh signaling via induction of Shh (38). IFN-g
stimulation induces Shh gene expression in cultured pri-
mary granular neuronal precursor cells, with subsequent
induction of the Hh target gene Gli1 (33). However, IFN-g
might also be capable of inhibiting canonical Hh-signaling
and Gli1 expression in neuronal stem cells in multiple
sclerosis and associated animal models (32).
Considering that CD8
+ T cells that produce IFN-g are
among the ﬁrst invaders of adipose tissue in obesity and
that Hh blocks white fat expansion in vivo (30), we hy-
pothesized that IFN-g might interfere with ongoing Hh
signaling and support increased adipocyte turnover. Using
a combination of in vitro and in vivo models we show that
IFN-g– and Hh-signaling pathways independently impair
white adipocyte differentiation. Surprisingly, costimulation
of both signaling cascades resulted in reciprocal cosup-
pression, relieving their individual antiadipogenic actions
and permitting adipogenesis. Our data demonstrate for the
ﬁrst time inhibition of Hh signaling via the IFN-g/Janus
kinase (Jak)/signal transducer and activator of transcription
(Stat1) axis in adipose tissue and suggest a novel antago-
nistic regulatory module to optimize white adipocyte
turnover according to the metabolic state.
RESEARCH DESIGN AND METHODS
Screening of Hh pathway activities using Shh-LIGHT2 and Ptch
2/2 cells.
Shh-LIGHT2 cells, a NIH-3T3–derived cell line generated to screen for Hh
pathway activities (39) were obtained from the American Type Culture Col-
lection (cat. CRL-2795, Manassas, VA) and cultured according to recom-
mended protocols (39). After reaching conﬂuence, cells were starved in
Dulbecco’s modiﬁed Eagle’s medium containing 0.5% FCS. Starved cells were
stimulated for 48 h with the synthetic Smoothened AGonist (SAG; ALEXIS
Biochemicals, San Diego, CA) or recombinant sonic Hh (Shh) protein (R&D
Systems, Minneapolis, MN) and/or IFN-g (BD Pharmingen, San Diego, CA), or
were left untreated. Jak proteins were inhibited by Jak Inhibitor I (Calbio-
chem, San Diego, CA). Primary ﬁbroblasts lacking functional Ptch (Ptch
2/2)
were derived from Ptch
2/2 mouse embryos (strain 003081, The Jackson
Laboratory, Bar Harbor, ME). After the cells had reached conﬂuence, they
were maintained in low-serum medium (0.5% FCS) and treated with IFN-g or
left untreated for 2 days. Hh signaling activities in Shh-LIGHT2 and Ptch
2/2
cells were measured using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI) or the Tropix galacto-light plus assay system (Tropix,
Bedford, MA), respectively. Signal intensities were normalized to Renilla lu-
ciferase (Shh-LIGHT2 cells) or total protein content (Ptch
2/2 cells), as de-
scribed (39).
Preparation and activation of T cells. CD8
+ lymphocytes were puriﬁed
from spleens from C57BL/6J mice using negative selection with IMag Strep-
tavidin Particles Plus-DM (BD Biosciences, Bedford, MA) according to the
manufacturer’s protocol. T cells were added to 48-well plates coated with 1
mg/mL anti-Cd3e and 3 mg/mL anti-Cd28 (both BD Pharmingen). Supernatants
of stimulated T cells were harvested after 48 h.
Cell culture and adipocyte differentiation. Mouse 3T3-L1 preadipocytes,
primary mouse, and human cells were isolated, propagated, and differentiated
as described ([30] and Supplementary Methods). Recombinant Shh (R&D
Systems), SAG (ALEXIS Biochemicals), and/or recombinant IFN-g (BD
Pharmingen) were added to the cells, as indicated in the text or Figure legends.
Oil Red O staining. For staining of neutral lipids, cells were ﬁxed and stained
with Oil Red O (OrO; Sigma-Aldrich, St. Louis, MO) according to standard
procedures. In brief, cells were washed with PBS and ﬁxed with 2% para-
formaldehyde in PBS at room temperature for 10 min. Fixed cells were washed
again with PBS and stained with OrO (1% w/v isopropanol, diluted 3:2 in PBS)
for 1 h at room temperature. Nuclei were counterstained with bromophenol
blue. Stained cells were washed and photographed.
Quantitative RT-PCR. Transcript levels were quantiﬁed as described in the
Supplementary Appendix.
Western blot analysis. Antibodies and detailed methods are described in the
Supplementary Appendix.
Isolation of primary mouse embryonic ﬁbroblasts. P r i m a r ym o u s ee m -
bryo ﬁbroblasts (MEFs) were derived from day 13.5 embryos obtained from
wild-type, Stat1
2/2 (40) and Ifngr1
2/2 (41) mice. MEFs were prepared as de-
scribed (42). All mice were of C57BL/6 background. The animal experiments
were discussed and approved by the ethics committee at the Institute of Animal
Breeding and Genetics, University of Veterinary Medicine Vienna and the
Austrian laws (GZ 68.205/0204-C/GT/2007 and GZ 68.205/0233-II/10b/2009).
Animal handling and treatment of mice with anti–IFN-g monoclonal
antibody. C57BL/6J mice were purchased from The Jackson Laboratory. At
age 6 weeks, male littermates were placed for 24 weeks on a high-fat (HF) diet
(HF group, n = 15, 60 kcal% fat, D12492) to induce obesity and on a low-fat
(LF) diet (LF group, n = 10, 10 kcal% fat, D12450B) to serve as lean controls
(both diets from Research Diets, New Brunswick, NJ). For the last 2 weeks of
diets, mice fed the HF diet were randomly split into two groups: HF and HF
treated with antibodies (HF+Ab, n = 5). HF+Ab mice were injected with 0.5
mg i.p. anti–IFN-g monoclonal antibodies (BD Pharmigen) three times within
the last 2 weeks of the diet. Control LF and HF animals received the same
amount of rat IgG (Sigma-Aldrich). All experimental protocols were approved
by the Institutional Animal Care and Use Committee at Medical University
Vienna (protocol no. BMWF-66.009/0066-II/106/2009), and all studies were
performed according to the methods approved in the protocol.
IFN-g and adiponectin ELISA. IFN-g and adiponectin levels in mouse serum
were determined by ELISA (R&D Systems). For details see Supplementary
Methods.
Adipose tissue fractionation. Digestion of perigonadal white fat pads was
performed as described previously (30). Adipose tissue macrophages were
isolated from stromal vascular fraction (SVF) cells using an antibody directed
against the panmacrophage marker F4/80 (eBiosciences, San Diego, CA)
coupled to magnetic beads (Miltenyi Biotech, Auburn, CA) according to the
manufacturer’s protocol.
Human samples and clinical parameters. The study included 25 obese
patients and 21 nonobese control subjects who underwent weight-reducing
surgery or elective surgical procedures such as cholecystectomy. Participants
were included if they had fasting plasma glucose levels ,7.0 mmol/L, no history
of diabetes or use of blood glucose–lowering medications, no weight changes
.3% during the previous 2 months, and C-reactive protein levels ,20 mg/L. To
reduce confounding by insulin resistance, obese subjects with a homeostasis
model assessment (HOMA) index .2.5 were excluded. All study subjects
provided informed consent, and the local ethics committee approved the study
protocols. Tissue biopsy specimens from visceral adipose tissue, obtained
during surgery, were collected in RNA-later (Ambion, Austin, TX) and stored
at 280°C until further processing. Plasma glucose, insulin, C-reactive protein
concentrations, and the HOMA index were determined as described (43).
Gene set enrichment analysis. Gene set enrichment analysis methods were
done as described in the Supplementary Appendix.
Statistical analyses. All data are shown as mean 6 SEM, unless otherwise
indicated. The signiﬁcance of differences between means was assessed by
two-tailed Student t test or ANOVA with the Tukey honestly signiﬁcance dif-
ference test post hoc, where appropriate. Differences between human study
groups were ascertained by ANOVA. We used multiple regression to adjust all
measurements for concomitant effects of sex and age. Adjustments for CD68
and CD144 were performed as indicated. Categoric data were summarized by
frequencies and analyzed by the x
2 test. All reported P values are two-tailed.
RESULTS
T-cell activation blocks Hh signaling in an IFN-g–
dependent manner. Previous studies have shown that
Hh signaling activity is diminished in the adipose tissue of
obese mice (29) and that CD8
+ T-cell inﬁltration is an early
hallmark of obese adipose tissue in both mice and humans
(17). To test whether the two phenomena are causally re-
lated, we examined the effects of activated T-cell super-
natants on the Hh-responsive luciferase reporter cell line
Shh-LIGHT2 (39). Addition of the Hh-activator SAG to Shh-
LIGHT2 cells robustly induces luciferase activity (Fig. 1A).
Intriguingly, cotreatment with supernatants from CD8
+
T cells activated in vitro with anti-CD3 and anti-CD28
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erase response. Importantly, the supernatant from rest-
ing T cells showed no inhibitory effect (Fig. 1A). To test
whether the observed effect was unique to Shh-LIGHT2
cells, we exposed 3T3-L1 preadipocytes to parallel
treatment conditions. In direct corroboration of the Shh-
LIGHT2 ﬁndings, the activated CD8
+ T-cell supernatant
substantially reduced SAG-induced Gli1 mRNA expres-
sion in 3T3-L1 cells (Fig. 1B). Once again, the addition of
supernatant from resting, rather than activated cells,
showed no effect. Importantly, the addition of anti–IFN-g–
blocking antibodies abolished the marked inhibitory effect
of the T-cell supernatant on Hh activation in both experi-
mental systems (Fig. 1A and B), directly implicating IFN-g
in the inhibition of Hh signaling in Shh-LIGHT2 cells and in
preadipocytes. Characterization of the potency of IFN-g–
mediated Hh inhibition revealed signiﬁcant effects at the
low nmol/L level in Shh-LIGHT2 cells (Fig. 1C). Indeed,
IFN-g alone was sufﬁcient to affect a nearly total block
of SAG-induced Hh activity. Importantly, these ﬁndings
were conﬁrmed pharmacologically using the endogenous
Shh ligand as well as genetically using ﬁbroblasts derived
from Ptch knockout mouse embryos (39) harboring con-
stitutive activation of Hh signaling and downstream target
genes (Fig. 1D and Supplementary Fig. 1). Thus, activated
CD8
+ T cells inhibit Hh signaling in an IFN-g–dependent
manner.
IFN-g rescues adipogenesis in vitro by overriding the
strong inhibitory effect of Hh signaling. To functionally
assess the inhibitory role of IFN-g on Hh signaling in adi-
pocytes, we induced 3T3-L1 cells to undergo adipogenesis
in the presence or absence of SAG, IFN-g, or vehicle for
10 days. In line with our previous data (30), SAG treatment
of 3T3-L1 cells completely blocked adipogenesis. These
effects were observed macroscopically with OrO staining
for lipid droplets (Fig. 2A and B), by quantitative PCR-based
expression proﬁling of the hallmark Hh target genes Gli1,
Hhip,a n dPtch1 (Fig. 2C), and on corresponding protein
levels of Gli1 and Hhip (Fig. 2D and Supplementary Fig. 2).
In keeping with the macroscopic ﬁndings, we ob-
served substantially reduced mRNA expression levels of
the key adipogenic markers Fabp4 and Adipoq as well as
the master regulators of adipogenesis, Cebpa and Pparg
(Fig. 2E). In line with published data, IFN-g also partially
blocked differentiation of 3T3-L1 cells with a reduction of
OrO-positive adipocytes and a decrease of key adipose-
speciﬁc markers ([20–22]; Fig. 2A, B,a n dE). Intriguingly,
whereas treatment of 3T3-L1 cells with IFN-g alone induced
a partial inhibitory effect on adipogenesis, simultaneous
activation of Hh and IFN-g signaling pathways in 3T3-L1
preadipocytes rescued any observable Hh-induced block
and restored nearly complete adipogenesis (Fig. 2A–E).
Restoration of differentiation capacity by coaddition of IFN-g
a n dS A Gw a sa s s o c i a t e dw i t h substantial reductions in
Hh target gene expression relative to SAG alone on both
the protein and the mRNA levels (Gli1 and Hhip; Fig. 2C and
D and Supplementary Fig. 2) as well as recovery of mRNA
expression for all key differentiation markers (Fabp4, Adipoq,
Cebpa,a n dPparg;F i g .2 E). Further, IFN-g treatment blunted
the SAG-induced increase of chicken ovalbumin upstream
promoter-transcription factor 2 (Coup-TF2) and Gata2 (Sup-
plementary Fig. 3), direct downstream mediators of Hh-
induced adipogenic block (30,44). Thus, IFN-g rescues
Hh-induced adipogenic block.
FIG. 1. Suppression of Shh signaling by activated T cells is IFN-g–dependent. A: Shh-LIGHT2 cells were cultured for 48 h with no stimulus, SAG
(200 nmol/L), SAG in the presence or absence of supernatant from resting or activated CD8
+ T cells, with or without anti–IFN-g monoclonal
antibody (25 ng/µL) and assayed for luciferase activity. B: 3T3-L1 preadipocytes were treated in the same way as described for the Shh-LIGHT2
cells above (SAG 20 nmol/L). Gli1 mRNA was measured by quantitative RT-PCR and normalized for ribosomal protein, large, P0, (Rplp0). C: Shh-
LIGHT2 cells were cultured for 48 h in the absence or presence of SAG plus the indicated concentrations of IFN-g and assayed for luciferase
activity. D: Conﬂuent Shh-LIGHT2 reporter cells were left untreated (Con), or treated with recombinant Shh (200 ng/mL), IFN-g (10 ng/mL), or
both, for 48 h. Data represent means 6 SEM of triplicate samples. *P < 0.05; **P < 0.01; ***P < 0.001.
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activation of Jak-Stat signaling. Among others, IFN-g
activates the Jak-Stat pathway (45). To test whether acti-
vated Jak-Stat signaling was responsible for inhibition of
SAG responses, we treated Shh-LIGHT2 cells with SAG
and/or IFN-g in the presence or absence of a pan-Jak in-
hibitor (JakInh) (46). As expected, of the single-compound
control wells, only SAG elicited a substantial luciferase
response (Fig. 3A). IFN-g and JakInh alone or combined
showed no signiﬁcant induction of Hh signaling. Surpris-
ingly, simultaneous treatment of cells with SAG (200 nmol/L)
and JakInh (2 mmol/L) resulted in a marked potentiation of
the Gli-induced luciferase activity compared with SAG
treatment alone (Fig. 3A). Critically, the addition of JakInh
to IFN-g/SAG costimulated wells also resulted in a po-
tentiated response compared with SAG alone, indicating
that IFN-g requires downstream Jak activity to inhibit
Hh signaling (Fig. 3A). Of note, there is evidence that
IFN-g can regulate the expression of select downstream
genes even in the absence of Stat1 (47). To address this
issue, we tested whether IFN-g suppression of Gli1 ex-
pression was maintained in MEFs isolated from IFN-g re-
ceptor 1–deﬁcient (Ifngr1
2/2) and Stat1-deﬁcient (Stat1
2/2)
mice. Importantly, we observed that the inhibitory effect of
IFN-g on Hh signaling was abolished in MEFs isolated from
both strains, direct genetic evidence implicating Ifngr1 and
Stat1 in Hh signaling control (Fig. 3B–D). Thus, IFN-g
inhibits Hh signaling via Infgr1-induced activation of Stat1.
To corroborate the 3T3-L1 studies, we attempted to test
Ifn-g- H hc r o s s - t a l ki nh u m a na n dm o u s ep r i m a r yw h i t e
preadipocytes. Because the key differentiation factors
3-isobutyl-1-methylxanthin (IBMX) and dexamethasone (Dex)
block Hh activation (30), 3T3-L1 and primary preadipocytes
were induced using a minimal induction medium containing
FIG. 2. IFN-g prevents SAG-induced inhibition of adipocyte differentiation. A: 3T3-L1 cells were induced to differentiate into adipocytes in the
presence of 20 nmol/L SAG and/or 50 ng/mL IFN-g or were left untreated (Con) for 10 days. OrO staining was performed 10 days after induction.
B: Adipocytes were counted under a bright-ﬁeld microscope and presented as the percentage of the total number of methylene blue–stained
nuclei. C: mRNA levels of Hh target genes (Gli1, Hhip,a n dPtch1) were measured by quantitative RT-PCR analysis and normalized to Rplp0.
D: Gli1 Western blot of whole-cell lysates. Heat shock protein 70 was used as the loading control. E: mRNA levels of marker genes of adipocyte
differentiation (aP2/Fabp4, Adipoq, Cebpa,a n dPparg) were measured by quantitative RT-PCR analysis. Data represent means 6 SEM of
triplicate samples. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not signiﬁcant. (A high-quality color representation of this ﬁgure is available in the
online issue.)
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ferentiation cocktail to successfully explore Hh signaling
effects of adipogenesis in 3T3-L1 cells (30). In contrast
to 3T3-L1 cells, induction of primary mouse and human
preadipocytes by the minimal induction medium was in-
sufﬁcient to induce substantial differentiation, even after
10 days.
Primary cells cultured in parallel under classical conditions
differentiated efﬁciently (Supplementary Fig. 4A and B).
IBMX/Dex completely blocked Hh activation by SAG
(Supplementary Fig. 4D). These ﬁndings were supported
by OrO staining of the same cells (Supplementary Fig. 4E
and F). We conﬁrmed this IBMX/Dex Hh–neutralizing
effect by qPCR of the Hh target gene Gli1 and the early
adipogenic marker peroxisome proliferator–activated
receptor-g (Ppar-g) 48 h after induction (Supplementary
Fig. 4G and H). Looking instead at preadipocytes, IFN-g
efﬁciently inhibited SAG-induced Gli1 mRNA expression
in both human and mouse primary cultures (Fig. 4A and
Supplementary Fig. 4I), providing strong evidence that
the appropriate signaling framework exists and is functional
in the human and mouse progenitor pool. Importantly, in
direct agreement with the ﬁndings in 3T3-L1 cells above,
addition of IFN-g attenuated SAG-induced Hh activation
and relieved Hh suppression of Pparg expression (Fig. 4B
and Supplementary Fig. 4J).
IFN-g depletion restores Hh signaling in adipose
tissue stromal vascular cells in vivo. Genetic-induced
and diet-induced obesity both decrease expression levels
of Hh target genes in perigonadal white fat pads of mice
(29). This is in accordance with antiadipogenic properties
of Hh signaling and the substantial generation of new
adipocytes during weight gain. However, the underlying
cause of this deregulation of Hh targets is not understood.
We examined the effects of IFN-g depletion on the ex-
pression of Hh target genes in obese adipose tissue using
an in vivo neutralizing antibody strategy. Male C57BL/6J
mice exposed to a HF diet for 22 weeks were randomly
assigned to a control group (HF; n = 10) or a group that
received intraperitoneal anti-IFN-g–neutralizing antibody
(HF+IFN-g-Ab; n = 5). Control animals were injected in
parallel with a control IgG antibody. Consistent with pre-
vious ﬁndings (20) IFN-g serum levels in the HF group
were signiﬁcantly higher than in animals fed normal chow
(Supplementary Fig. 5). Immunoneutralization in the treated
animals was similarly conﬁrmed by ELISA.
As expected, body weight, fasted blood glucose levels,
perigonadal fat mass, adipose tissue inﬁltration with Mac2
+
macrophages, and adipocyte size were signiﬁcantly higher
in HF fed mice relative to LF fed controls (Supplemen-
tary Table 1 and Supplementary Fig. 6A–K ). Anti–IFN-g–
neutralizing antibody treatment for 2 weeks did not
signiﬁcantly affect any of these gross metabolic parameters
(Supplementary Table 1 and Supplementary Fig. 6A–K). To
characterize the system, we compared Hh signaling activity
in adipose tissue fractionated into mature adipocytes,
macrophages, and macrophage-depleted stromal vascular
cells. In line with the role of Hh signaling in inhibiting
fat formation, the Hh target Gli1 showed low expression
in mature adipocytes compared with macrophage- and
macrophage-depleted stromal vascular fractions (dSVF).
Indeed, the highest Gli1 mRNA expression levels were found
in the macrophage fraction (Fig. 5A). Further, Gli1 ex-
pression in all three adipose tissue compartments was
FIG. 3. IFN-g prevents SAG-induced inhibition of adipocyte differentiation via Jak-Stat signaling. A: Shh-LIGHT2 cells were treated with 200 nmol/L
SAG and/or 25 ng/µLI F N - g in the absence or presence of JakInh. Simultaneous treatment of cells with SAG and JakInh resulted in an additional
increase in relative Gli1 luciferase activity compared with SAG only–treated cells. B–D: We also tested whether effects of IFN-g on Gli1 expression
could persist in MEFs from Ifngr1
2/2 and Stat1
2/2 mice. The inhibitory effect of IFN-g on Shh signaling was cancelled in Ifngr1
2/2 and Stat1
2/2 MEFs.
These experiments demonstrate that IFN-g acts by means of the Jak-Stat pathway to abrogate the effects of Shh signaling. Data represent means 6
SEM of triplicate samples. *P < 0.01; **P < 0.001; NS, not signiﬁcant.
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treated control animals, suggesting that the HF diet im-
posed a broad suppressive effect on Hh activity in adipose
tissue (Fig. 5B).
Intriguingly, examination of expression proﬁles from
IFN-g–depleted animals suggested that IFN-g mediates Hh-
suppression in adipose tissue in vivo. Immunoneutraliza-
tion substantially reversed HF-induced suppression of the
downstream Hh target Gli1 (greater than twofold), and
impressively, completely restored expression of the target
Hhip to normal chow levels (;20-fold increase; Fig. 5C
and D). Critically, the Hh target Nr2f2/Coup-Tf2 also
showed restoration of expression (Supplementary Fig. 7),
as did the key insulin-sensitizing adipokine adiponectin
(Adipoq; Fig. 5E). This latter ﬁnding correlated directly
with increased serum adiponectin levels in immunoneu-
tralized animals (Supplementary Fig. 8).
Together, these data identify Hh signaling as a target of
IFN-g in adipose tissue in vivo and support a functional
role for their cross-talk in balancing adipose tissue func-
tion. Thus, IFN-g mediates functional suppression of Hh
signaling by a HF diet in vivo.
Hh signaling is downregulated in human obesity. Next,
we determined GLI1 transcript levels in human intra-
peritoneal adipose tissue of lean and insulin sensitive (IS)
obese subjects. This design allowed us to detect potential
associations of Hh signaling activity with intraperitoneal
adipose tissue expandability in humans without confound-
ing interference of insulin resistance. Despite a slight age
and sex variation in this unique patient set, no differences
were observed in plasma glucose and insulin levels or in the
HOMA index (Supplementary Table 2). GLUT4 expression
values were similar in both groups, reﬂecting the equal
presence of glucose transporters (Table 1). In line with
current knowledge, IS obese subjects did not show in-
creased CD68 expression levels or alterations in the en-
dothelial marker VE-cadherin (CD144). However, and in
line with our hypothesis that increased Hh activity inhibits
adipose tissue expansion, GLI1 expression was signiﬁcantly
decreased in adipose tissue samples of IS obese subjects
(P = 0.0237). Importantly, adjusting for age, sex, CD68, and
CD144 did not affect any of the statistical results, suggesting
that decreased GLI1 levels in IS obese subjects are not due
to changes in vascularization or macrophage inﬁltration
(Table 1). These ﬁndings highlight reduced Hh activity in
patients with a likely intact expandable progenitor pool
and no evidence of immune cell inﬁltration.
Next, we sought additional, more generalized evidence
where inﬂammation is present. We used gene set enrich-
ment to analyze publically available adipose tissue ex-
pression arrays from two of the best genetically controlled
human obesity cohorts, Pima Indians (GEO Reference
Series GSE2508) and a set of 13 pairs of monozygotic twins
discordant for adiposity (EBI-EMBL Reference Series
E-MEXP-1425). Not without surprise, pathway enrichment
for Th1/Th2 T-cell differentiation markers, a surrogate for
T-cell inﬁltration, exhibited robust enrichment in obese
Pima Indian and obese MZ-twin adipose tissues (FDR 0.08
and 0.16, respectively; nom. P = 0.006 and P = 0.01,
respectively; Supplementary Fig. 9). Intriguingly, and
with equally robust signal intensity to that of the Th1/Th2
pathway, Hh signaling exhibited an enrichment signal in the
control subjects of both genetically distinct cohorts, in-
dicating consistent downregulation of the pathway in both
obesity cohorts (FDR 0.08 and 0.12, respectively; nom. P =
0.08 and P = 0.12, respectively).
These ﬁndings indicate that in the absence of in-
ﬂammation, low Hh signaling is associated with insulin
sensitivity and, presumably, a highly plastic progenitor pool,
and that T-cell inﬁltration correlates highly with suppressed
Hh signaling in human adipose tissue.
DISCUSSION
Understanding the molecular mechanisms involved in
adipocyte differentiation is of great importance because it
may lead to new ways of treating obesity and, in particular,
its associated metabolic complications. Hh signaling and
IFN-g already have an established role in inhibiting adipo-
genesis (21,22,29,30).
Here we demonstrate for the ﬁrst time that inhibition of
adipocyte differentiation by Hh signaling can be balanced
FIG. 4. IFN-g inhibits Hh signaling in mouse primary preadipocytes. Mouse primary preadipocytes were cultured in medium containing insulin and
troglitazone for induction of adipogenic markers or in medium without any adipogenic inducers (Pre). Induced cells were stimulated with the Hh
agonist SAG (200 nmol/L) and/or 50 ng/mL IFN-g or left untreated (Con) for 48 h. A–B: Quantitative RT-PCR monitoring of Hh target gene Gli1 and
adipogenic marker Pparg. mRNA levels of the genes of interest were normalized to Rplp0. Data represent means 6 SEM of triplicate samples. *P <
0.05; ***P < 0.001; NS, not signiﬁcant.
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served in 3T3-L1 adipocytes (Fig. 2A–E) as well as in three
different primary culture systems—mouse embryonic ﬁbro-
blasts (Fig. 3B–D), primary mouse preadipocytes (Fig. 4A
and B), and primary human preadipocytes (Supplementary
Fig. 4I and J). These data, as well as recapitulation of the
phenotype using the endogenous Shh ligand, rule out cell-line
or chemical artifacts. The difﬁculty associated with re-
capitulating these studies in mature primary adipocytes
is caused by the direct inhibition of Hh signaling by both
IBMX and Dex, required constituents of primary adipocyte
differentiation cocktails.
Cross-talk between the Hh signaling pathway and IFN-g
has already been shown to inﬂuence cell differentiation
a n dp r o l i f e r a t i o ni ns p e c i ﬁc neuronal settings (31–33). IFN-g
indirectly regulates proliferation of neuronal precursor
cells through mechanisms involving elevated expression
of Shh and its major target genes, Gli1 and Ptch (31). Dis-
cordant upregulation of Shh by IFN-g, while suppressing
its target Gli1, was observed in studies on the differenti-
ation of neuronal stem cells (32). Interestingly, our studies
demonstrate that IFN-g–mediated inhibition of Hh target
genes (Gli1, Ptch, Hhip,a n dNr2f2/Coup-Tf2)i n3 T 3 - L 1
cells promotes adipocyte differentiation. IFN-g not only
rescued adipocyte differentiation but also decreased Coup-
Tf2 and Gata2 levels, further supporting an antiadipogenic
role of both genes (32). Thus, it appears that IFN-g sig-
naling can have very context-dependent effects on Hh
signaling.
After binding of IFN-g to its receptor, Jak1 and Jak2 are
activated and regulate downstream phosphorylation of
Stat1 (46). Although Stat1 is required for many IFN-g–
dependent actions, evidence shows that in the absence of
Stat1, IFN-g can still regulate the expression of some genes
(46,47). Because IFN-g–mediated inhibition of Hh signal-
ing did not occur in Stat1
2/2 MEFs, we conclude that this
cross-talk depends on Stat1. Interestingly, blocking con-
stitutive Jak-Stat activation by a pan-Jak inhibitor resulted
in greatly increased Gli1 luciferase activities in SAG-treated
Shh-LIGHT2 cells, even in the absence of IFN-g.T h i ss u g -
gests that basal Jak activity exerts an inhibitory tone on Hh
pathway activation.
Because the concentration of IFN-g is elevated in obe-
sity and the Hh signaling pathway was less active in obese
compared with lean mice, we hypothesized that IFN-g might
inhibit Hh signaling in vivo. Interestingly, when examining
FIG. 5. IFN-g inhibits Hh signaling in obesity in vivo. A–B: C57BL/6J mice were fed a LF or HF diet for 24 weeks (n = 10 or 15 mice per group,
respectively). For the last 2 weeks of diets, mice fed the HF diet were randomly split into HF and HF+Ab groups. The HF+Ab (n = 5) group was
treated with monoclonal antibodies against IFN-g. Adipose tissue was separated into adipocytes (Ad), macrophage fraction (MF), and macro-
phage-dSVF using magnetic immunoafﬁnity isolation. Cell fractions from mice fed LF and HF diets were analyzed for Gli1 mRNA expression. C–E:
dSVF from mice fed LF and HF diets was analyzed for Gli1, Hhip, and Adipoq.* P < 0.05; **P < 0.01.
TABLE 1
Comparison of intraperitoneal adipose mRNA expression levels
in lean vs. obese study subjects (n = 46)
Gene
Lean
(n = 21)
Obese
(n = 25) Adjusted for P*
GLUT4 5.77 (0.70) 4.78 (0.43) Sex, age NS
CD68 3.38 (0.39) 3.03 (0.29) Sex, age NS
CD144 8.18 (0.81) 10.16 (0.77) Sex, age NS
GLI1 7.46 (0.79) 5.17 (0.39) Sex, age 0.0237
GLI1 7.54 (0.79) 5.32 (0.39) Sex, age, CD68 0.0224
GLI1 7.80 (0.79) 5.06 (0.39) Sex, age, CD144 0.0049
GLI1 7.85 (0.79) 5.27 (0.39) Sex, age, CD68, CD144 0.0065
Data are arbitrary units and presented as mean 6 SEM. *P values
obtained from ANOVA. NS, not signiﬁcant.
IFN-g-Hh SIGNALING CROSS-TALK IN ADIPOGENESIS
1674 DIABETES, VOL. 60, JUNE 2011 diabetes.diabetesjournals.orgadipose tissue fractions for differences in Gli1 expression
in the lean and obese state, we found low Gli1 expression in
mature adipocytes. Levels of mRNA in dSVF were .20-fold
and in macrophages .40-fold higher than in the adipocyte
fraction. This is in accordance with previous data that show
decreased expression of positively acting Hh components
(Smo and the Glis) during adipogenesis (29,30). To de-
termine whether reduced expression of Hh target genes
in white fat of obese animals depends on higher IFN-g
concentrations in obesity, we treated obese mice with a
neutralizing antibody against IFN-g. Our results demon-
strate that obesity-associated repression of Hh-target genes
like Gli1 and Hhip in the dSVF was partially or completely
relieved by inhibiting IFN-g elicited Jak/Stat signaling. This
suggests that IFN-g opposes inhibition of Hh signaling in
obese adipose tissue in vivo.
Increases in fat mass can involve both hypertrophy and
hyperplasia of adipocytes. Obesity in adults is typically
associated with adipocyte hypertrophy, and an additional
adipocyte hyperplasia occurs in morbidly obese humans
and rodents (48–50). Adiposity-induced cellular and tissue
hypoxia is an important contributor to adipose tissue
immunopathies and adipocyte and adipose tissue dys-
function (2,8,9,16). Data suggest that the initial hypertro-
phic response of adipocytes promotes necrotic-like death,
after which the lipid storage capacity of adipose tissue can
be efﬁciently maintained or increased only by adipocyte
hyperplasia. Interestingly, current concepts support that
early adipose tissue expandability prevents metabolic
consequences like insulin resistance, even in morbid obe-
sity (9).
Some have proposed that the generation of new adipo-
cytes may be balanced by adipocyte death, with the constant
and tightly regulated total number set by early adulthood
(50). Our ﬁndings suggest a model where the inhibition of
H hs i g n a l i n gb yI F N - g in obesity contributes to the de-
velopment of new adipocytes (Fig. 6). At steady-state in
lean individuals, basal Hh-pathway activity prevents the
formation of new adipocytes. T-cell inﬁltration, as an
early event in obesity development, leads to elevated IFN-g
production in adipose tissue and inhibition of Hh-signaling,
a scenario that is permissive for the recruitment and de-
velopment of new adipocyte populations. Such an early
inhibition of Hh signaling may be a prerequisite for com-
pensatory increases in total adipocyte numbers, although
that is speculation.
Our observation that the main Hh target gene GLI1
is downregulated in intraperitoneal adipose tissue from
metabolically healthy IS obese subjects supports the con-
cept that early inactivation of Hh signaling and subsequent
release of the intracellular progenitor pool to expansion
might alleviate obesity associated insulin resistance. Clearly
though, the system is more complex. Indeed, robust op-
posing signals for T-cell inﬁltration (upregulated) and Hh
signaling (downregulated) in the adipose tissue of MZ twins
as well as in Pima Indian cohorts support the idea that in-
hibition of Hh signaling alone is insufﬁcient to block pa-
thologies associated with obesity and chronic inﬂammation
(Supplementary Fig. 9). It is almost certain that additional
positive expansion signals are required for proper ex-
pansion. A deeper understanding of these concepts will
be aided by long-term genetic dissections in vivo, using for
instance inducible adipose tissue speciﬁcI F N - g receptor–
deﬁcient mice.
In conclusion, we have established for the ﬁrst time that
IFN-g directly inhibits Hh signaling in (pre)adipocytes in
vitro and in adipose tissue in vivo. Our results suggest that
the cross-talk between IFN-g and the Hh-signaling pathway
is essential in the maintenance of optimal adipocyte dif-
ferentiation. The ability to control the plasticity of adipo-
cyte turnover would be a powerful tool in alleviating many
complications associated with obesity. That Hh antago-
nists will one day be used for such purposes in the clinic is
perhaps a stretch. However, understanding the regulatory
architecture that controls the progenitor cell decision “To
differentiate, or not to differentiate?” will be critical to the
development of any such therapies. We believe we have
added one of the ﬁrst pieces with which to construct this
complex puzzle.
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FIG. 6. Model shows a novel cross-talk mechanism between IFN-g and
Hh signaling maintains adipogenesis in adipose tissue. Activation of Hh
signaling blocks white adipocyte differentiation. T cells inﬁltrating
white adipose tissue early during the development of obesity secrete
IFN-g and thus inhibit ongoing Hh signaling. Decreased Hh signaling
activity in (pre)adipocytes rescues adipogenesis.
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